Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016', provides in depth analysis on E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted pipeline therapeutics. The report provides comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects - The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Overview 8 Therapeutics Development 9 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Stage of Development 9 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Therapy Area 10 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Indication 11 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Companies 15 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Products under Development by Universities/Institutes 19 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment 21 Assessment by Monotherapy/Combination Products 21 Assessment by Mechanism of Action 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development 27 Aileron Therapeutics, Inc. 27 Amgen Inc. 28 Ascentage Pharma Group Corporation, Ltd. 29 Daiichi Sankyo Company, Limited 30 F. Hoffmann-La Roche Ltd. 31 Merck & Co., Inc. 32 Novartis AG 33 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles 34 ALRN-6924 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 AM-7209 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 AMG-232 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 APG-115 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 ATSP-7041 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 CGM-097 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 DS-3032 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 DS-5272 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 HDM-201 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 idasanutlin - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 ISA-27 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 MI-888 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 MK-8242 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 MMRi-64 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 nutlin-3 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 R-xxx - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 RG-7775 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 RO-8994 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecule 1 to Inhibit MDM2 for Oncology - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecule 2 to Inhibit MDM2 for Oncology - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Small Molecule 3 to Inhibit MDM2 for Oncology - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecules to Inhibit MDM2 for Breast Cancer - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Small Molecules to Inhibit p53-hdm2 for Oncology - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Small Molecules to Inhibit p53-MDM2 Interaction for Cancer - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Projects 64 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products 67 E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Featured News & Press Releases 68 Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53 68 Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH 69 Aug 15, 2013: Aileron Therapeutics Publishes Data Demonstrating ATSP-7041 as First-in-class p53 Pathway Re-activator for the Treatment of Solid and Hematologic Cancers 69 Nov 07, 2012: Aileron Therapeutics Presents New Data On Stapled Peptide Oncology Program At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 70 Oct 31, 2012: Aileron Therapeutics To Present Data On Stapled Peptides At Upcoming Scientific Conferences And Industry Events 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development for, H2 2016 9 Number of Products under Development by Therapy Area, H2 2016 10 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Products under Development by Companies, H2 2016 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2016 19 Products under Investigation by Universities/Institutes, H2 2016 20 Assessment by Monotherapy/Combination Products, H2 2016 21 Number of Products by Stage and Mechanism of Action, H2 2016 22 Number of Products by Stage and Route of Administration, H2 2016 24 Number of Products by Stage and Molecule Type, H2 2016 26 Pipeline by Aileron Therapeutics, Inc., H2 2016 27 Pipeline by Amgen Inc., H2 2016 28 Pipeline by Ascentage Pharma Group Corporation, Ltd., H2 2016 29 Pipeline by Daiichi Sankyo Company, Limited, H2 2016 30 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 31 Pipeline by Merck & Co., Inc., H2 2016 32 Pipeline by Novartis AG, H2 2016 33 Dormant Projects, H2 2016 64 Dormant Projects (Contd..1), H2 2016 65 Dormant Projects (Contd..2), H2 2016 66 Discontinued Products, H2 2016 67
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
